Immunotherapy has made remarkable strides in cancer therapy over the past decade.
However, such emerging therapy still suffers from the low response rates and immune …

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …

Cancer immunotherapy has been accompanied by promising results over the past few
years. Programmed Cell Death Protein 1 (PD-1) plays a vital role in inhibiting immune …

Ovarian cancer response to immunotherapy is limited; however, the evaluation of
sensitive/resistant target treatment subpopulations based on stratification by tumor …

Cancer is still the leading cause of death globally. The approval of the therapeutic use of
monoclonal antibodies against immune checkpoint molecules, notably those that target the …

Immune checkpoint proteins (ICP) are currently one of the most novel and promising areas
of immune-oncology research. This novel way of targeting tumor cells has shown favorable …

Packaging multiple drugs into a nanocarrier with rational design to achieve synergistic
cancer therapy remains a challenge due to the intrinsically varied pharmacodynamics of …

Aim: Despite the similarities in the pathogenesis of the beta coronaviruses, the precise
infective mechanisms of SARS-CoV-2 remain unclear. Objective: In this review, we aim to …

Background Ovarian carcinoma (OC) is a prevalent gynecological malignancy associated
with high recurrence rates and mortality, often diagnosed at advanced stages. Despite …

Breast cancer is a heterogeneous disorder with different molecular subtypes and biological
characteristics for which there are diverse therapeutic approaches and clinical outcomes …